The potent systemic immunosuppression therapy necessary to sustain a life-saving solid organ transplant is associated with an increased incidence of various infections including human papillomavirus infection and skin cancers in organ transplant recipients. Imiquimod, a topical agent that functions through local induction of a specific anti-viral or anti-tumor immune response, appears to be a promising therapeutic option that could potentially counteract in situ the effects of systemic immunosupression in this vulnerable group. Up-to-date studies using this local immune-response modifier in transplanted patients have yielded reassuring and encouraging results regarding its safety and efficacy in this population. However, in order to establish the use of imiquimod as a standard treatment option for organ transplant recipients, additional research and clinical trials are required.
The past decades have seen unprecedented progress in the development of solid organ transplantation as a therapeutic choice for endstage organ disease. Organ Transplant Recipients (OTR) live longer, have a good quality of life and represent a rapidly growing population of people with specific medical needs. As the number of solid organ transplants continues to rise, so too does the number of various infections including human papillomavirus (HPV) infections and skin cancers in OTR. Consequently, physicians will be called upon to manage these diseases in the sensitive OTR population and to develop novel therapeutic and preventive strategies to better deal with them.
The clinical efficacy of imiquimod 5% cream (a topical therapy approved for genital warts, actinic keratoses and superficial basal cell carcinoma) stems from stimulation ofinnate and cell-mediated immune responses, resulting in antiviral, antiproliferative and antitumor activity. Because of these properties, imiquimod and other members of this family of immune response modifiers are potential agents for treatment of conditions where the immune system can affect the regression of the disease (1) . In light of the role of systemic immunosupression in the development of cutaneous infections and neoplasms in OTR, the use of imiquimod to locally stimulate immune responses against cancerous, pre-cancerous and viral lesions appears as a promising option of treatment counteracting in situ the effects ofsystemic immunosupression (2) .
Our article briefly reviews the therapeutic trials and reports on the innovative uses of imiquimod in OTR, and could therefore be used as a resource for physicians treating this group of patients with aggressive, refractory or recalcitrant skin diseases.
OTR patients: a vulnerable population with particular needs
The etiology of post-transplant malignancy is believed to be multifactorial and likely involves impaired immunosurveillance of neoplastic cells, as well as depressed antiviral immune activity with a number of common post-transplant malignancies being viral-related (3) . After renal transplantation, the principal neoplasms and their associated viruses are lymphoproliferative disorders due to Epstein-Barr virus, Kaposi's sarcoma (KS) due to human herpes virus 8 (HHV-8), and squamous cell carcinoma (SCC) due to human papilloma virus(HPV) (3) . Registered data show that there is an overall 3-5fold increase of cancer risk in transplant recipients compared with the general population, with skin cancers and lymphoma particularly prevalent (4) . As compared with an age-matched healthy population or with patients undergoing dialysis, OTR have an increased incidence of cancer; one study found that after 20 years of immunosuppressive therapy, 40 percent of recipients had cancer. Significantly increased rates in transplant recipients were observed for leukaemia, renal cancer, mouth and oesophageal cancer, melanoma, non-melanoma skin cancers (NMSC), lymphoma and KS (4) . Further burdens are to be expected in an aging population of transplant recipients with well-functioning allografts. The type of drugs used for the induction and maintenance of immunosuppression, and the intensity and duration of treatment with these agents influence both the incidence and the type of cancer that develops (4) (5) .
Skin cancers are the most common malignant conditions in OTR (6) and account for substantial morbidity and mortality in these patients. Among all skin neoplasms, non-melanoma skin cancers (NMSC) are the most frequent in such patients, who show a very high incidence of SCC and basal cell carcinomas (BCC), as well as of actinic keratoses (AK), which are considered precursor lesions, but can also be regarded as true in situ SCC (5, (7) (8) . SCC and BCC account for more than 90 percent of all skin cancers in transplant recipients (6, 9) .
The incidence of NMSC increases with the duration of immunosuppressive therapy, ultimately affecting 50 percent or more of Caucasian transplant recipients (6, (9) (10) . SCC occurs 65-250 times more frequently in OTR than in the general population (10), while the incidence of BCC is reportedly increased in OTR by a factor of 10 (10) . The risk appears to increase linearly for BCC and exponentially for SCC; thus, the ratio of SCC to BCC in patients without transplants (1:4) is reversed in transplant recipients (9) .
Very often skin cancers in transplant recipients show clinical aspects unusual in the general population: they may be highly aggressive and invasive (11), and may develop, particularly SCC, in a very short time. They recur locally in 13.4% of patients, generally during the first six months after excision, and metastasize in 5 to 9% of patients, usually during the second year after excision with a 50% mortality rate in patients with metastases (2, 11) . AK also progress more rapidly and frequently than normal into SCC, which in turn exhibits a stronger tendency to metastasize. AK has been calculated to appear 15 years earlier on average in OTR than in a control population (55 versus 70 years) (12) The incidence of KS is much higher in transplant recipients than innon-immunosuppressedpopulations (by a factor of 84 to 500) (13) . The incidence of KS increases with duration of immunosuppressive treatment, with actually more than 5% of all de novo tumors in this group of patients being KS (13) . The prevalence of KS in transplant recipients varies depending on geographical location, ranging from 0.5% in Western countries, such as the USA, to 5.3% in Saudi Arabia (6) . Similar to the other forms of KS, also in transplant recipients this tumor is more frequent in males. KS often occurs early after transplantation with the time to the onset of disease ranging from 5 to 21 months post-transplant (6, (13) (14) , however, it has been reported as late as 18 years post-transplant (6) .
Warts are one of the cutaneous viral diseases that commonly insurge and are notoriously persistent in immunocompromised individuals. OTR patients unable to mount an adequate T-helper I (Th1) cellmediated immune response are rather susceptible to HPV infection and may develop extensive viral warts which tend to be painful, persistent and recalcitrant to treatment (15) . The incidence of warts parallels the level and duration of immunosuppression. For example, up to 50% of renal transplant recipients have cutaneous warts at 1 year and 77-95% and have warts at 5 years' post-transplant (16) . Progression of these warts to dysplastic lesions and SCC has also been documented (17) . Although the precise role of HPV in the pathogenesis of skin cancers in OTR is not clear, an increased prevalence of HPV is found in the SCC of immunosuppressed OTR, particularly oncogenic types 5 and 8 (18) .
Considering the large numbers and extensive lesions of malignancies or warts often with aggressive behavior found in OTR, treatment at the precancerous or localized stages is of paramount importance to minimize morbidity and mortality. In a population often subjected to multiple surgical excisions and destructive therapies, a self-applied topical therapy for viral warts and precancerous and malignant neoplasms constitutes a promising new weapon in the quiver of therapeutic ammunition (2) .
Imiquimod: A promising topical immunostimulatory agent for dermatological use
Imiquimod (1-(2-methy1propyl)-lH-imidazo[4,5c]quinolin-4-amine) is one of the first molecules of a new class of drugs known as immune response modifiers. It belongs to the family of imidazoquinolines, which have potent antiviral and anti-tumor properties (19) via stimulation of innate and acquired cellular immune responses. Commercially it exists as a 5% cream that induces its therapeutic effects by topical application.
The mode of action of imiquimod appears to comprise several presumably mutually enhancing components (20) . Imiquimod directly activates innate immune effectors through a Toll-like receptor (TLR) 7/MyD88-dependent pathway (21) . Upon TLR stimulation, nuclear factor-kappaB activation and the interferon (IFN)-regulatory factor 3 pathway initiate production of pro-inflammatory cytokines, such as interleukin-1 and tumor necrosis factoralpha, and production of type I IFNs (IFN-alpha and IFN-beta), respectively (21) . This in turn drives adaptive immunity toward a T helper type I immune response, either directly through the induction of IFN-y in T cells or indirectly through the promotion of dendritic cell maturation (22) .
It is thought that the effects of imiquimod on epidermal Langerhans cells (LC) are an important mechanism of action by which imiquimod induces Thl-dominant cellular immune responses in situ during the treatment of external genital warts and basal cell carcinoma (23) . In vivo, with topical application ofimiquimod to mouse skin, migration of LC is induced from the epidermis to the local lymph node (24) . It has been demonstrated that imiquimod and its hydroxylated derivative, R848, also induce maturation of human epidermal LC, enhanced IL-12 production, and significantly increase IFN-y production by CD4+T-Iymphocytes during antigen presentation by imiquimod-treated LC compared to control LC (25) .
Imiquimod-associated antitumor responses also involve the induction of apoptosis, as shown in SCC cell lines and superficial BCC in vivo (26) . This novel mode of action appears to be independent of membrane-bound death receptors, but involves caspase activation. Induction of apoptosis by imiquimod is, at least in part, presumably mediated through Bcl-2-dependent release of mitochondrial cytochrome c and subsequent activation of caspase-9 (27) .
These preclinical properties have translated well in the clinical use of imiquimod, which has been proved to be effective for the treatment of external genital warts, actinic keratosis, and basal cell carcinoma (28) . Topical imiquimod has also been used in a variety of different skin disorders including nodular and superficial BCC (29) , in situ and invasive SCC (30-31), lentigo maligna (32), lentigo maligna melanoma (33), keratoacanthomas (34) , primary cutaneous CD30 positive anaplastic large cell lymphoma (35) , mycosis fungoides (36), extramammary Paget's disease (37) , cutaneous melanoma metastases (38) , cutaneous warts and molluscum contagiosum (39) , stucco keratosis (40), cutaneous leishmaniasis (41) and keloids (42) .
Reported clinical use ofimiquimod in OTR patients
Imiquimod appears attractive as a therapeutic option for OTR patients owing to its activation of the local cutaneous immune system. However, in the setting of systemic iatrogenic immunosuppression used to prevent graft rejection, the question is whether imiquimod is able to generate a sufficient immune response for effective antiviral and antitumor effects. Another issue of paramount importance that has also to be addressed for this population is the safety of a topical immunostimulant in patients with allografts (43) .
These issues have already been addressed previously in a 2005 review by Kovach and Stasko (2) .,.Since then a series of interesting reports and studies has been published adding thus to our knowledge on the clinical experience of imiquimod use in this group of patients.
Safety ofthe treatment
There is a theoretical risk that imiquimod can induce a systemic immunostimulation, thereby jeopardizing the viability of a transplanted organ. There has been one single report of systemic immunostimulation: flaring of an HLA-B27 spondyloarthropathy, previously controlled by immunosuppressive medications, after 2 weeks of treatment with imiquimod 5% cream applied three times weekly for cervical and vulvar warts in a non-transplant patient (43) . Although systemic absorption of the drug could trigger a systemic immunostimulation, available pharmacokinetic data are reassuring: they demonstrate insignificant systemic absorption of topically applied imiquimod (44) .
To date there are 14 studies/reports presenting more than 100 OTR patients treated for various skin diseases with imiquimod following different treatment schedules, but to our knowledge there has been no serious systemic event associated with the use of this compound. No graft rejection associated with the use of imiquimod was reported.
In a study on the treatment of recalcitrant cutaneous warts (45) a transient rise in creatinine was measured in three renal transplant recipients but this was considered by the authors as unrelated to imiquimod exposure. In a randomized, doubleblind, placebo-controlled study evaluating the safety and efficacy of 5% imiquimod for the treatment of skin dysplasia in high risk renal transplant recipients (46) , mean serum creatinine levels were compared with mean values 12 months before the study and during the 8 months after treatment. A 20 to 60 em' skin area was treated 3 times per week for 16 weeks or until all lesions cleared at the application site with similarly packaged single-dose sachets [each containing 250 mg of either 5% imiquimod (12.5mg ofactive ingredient) or matching placebo cream]. No patient showed more than a 20% increase in serum creatinine concentration during the 16 weeks of treatment suggesting that imiquimod treatment to a limited area of skin does not have any adverse effect on renal function in renal transplanted recipients. In another randomized, placebo-controlled safety and efficacy study of imiquimod 5% cream for Actinic Keratoses in Kidney-, Heart-, and Liver Transplant Patients a blinded independent expert committee was responsible for monitoring the safety of the grafts (47), A total of 43 OTR patients applied 2 cachets (500 mg) of topical imiquimod or vehicle cream 3 times weekly to a 100 em' area. No serious adverse events were considered related to the study drug. Possibly related adverse events in the 29 patients randomized to imiquimod were fatigue (1/29), headache(1/29), diarrhea (1/29), nausea (1/ 29), rash (1/29), skin disorder (1/29) and leucopenia (1/29). No meaningful trends were observed in laboratory results for creatinine, transaminases and C-reactive protein or other laboratory markers. This study explored a substantial safety margin by using a double dose of imiquimod than that used by Brown and co-authors (46) but it confirmed the safety of this treatment for grafted organs.
Overall, up-to-date studies are rather reassuring for the safety of imiquimod in patients with allografts since to date neither clinically relevant systemic alterations ofimmune function nor adverse effects on transplanted organs have been reported, suggesting that imiquimod's immunostimulating effects are probably limited to the site of application.
Local side effects
Local skin reactions on the imiquimod application area are the most common reported adverse reactions and usually comprise erythema, pruritus, superficial erosions, and crusting. The reactions are usually mild and do not necessitate treatment interruption, though in some cases moderate local reactions led to discontinuation of drug application for 1 to 2 weeks or even less often to treatment interruption. The local skin reaction in the OTR patients treated with imiquimod (46) (47) (48) seemed to be similar in intensity but delayed in appearance and less frequent when compared to immunocompetent patients (49) and may reflect a failure to recruit the effector cells needed to stimulate the cutaneous immune system of immunosuppressed individuals.
Efficacy oftreatment
There has been a series ofreports on the beneficial effects of imiquimod for a variety of different skin diseases.
Basal cell carcinoma
In an open-label uncontrolled study on 4 renal and I cardiac transplant recipients using imiquimod 5% with a total of 24 applications either 4 times weekly for 6 weeks or 5 nights weekly for 5 weeks, clinical and histological clearance ofthe lesions was reported (50) . The lesions were 4 superficial BCC, 3 nodular BCC and 3 infiltrative BCC. All superficial BCC (4/ 4) resolved without relapse over a mean of 8 months of follow-up while this was noted in 2 out of 3 of the nodular BCC and 1 of the three infiltrative BCe. The 7 BCC that responded to treatment were small tumors (mean tumor area 52 mm-), located mainly on the trunk, with a non-aggressive histological pattern and with erythema (517) and erosion (517) at the end of treatment. The three BCC that did not respond to the treatment were large tumors (mean tumor area 104.7 mm-), mainly on the head, infiltrative, and without erosion at the end of treatment. Due to the small numbers of this study we cannot draw accurate conclusions but it appears that imiquimod is more effective in superficial BCe.
Actinic keratosis, Bowenoid Papulosis and skin dysplasia
Areas of "field change" and premalignant cutaneous lesions in OTR patients have high malignant potential and therefore their treatment with imiquimod could be potentially very beneficial for this group of patients. There has recently been a series of publications on the use of imiquimod for such indications. In a first study (51) reporting the use of imiquimod two to three times weekly for 12 to 16 weeks on multiple AK in 6 OTR patients, total clearance for five out of six patients was demonstrated histologically. In the first randomized, double-blinded and placebo controlled study on high risk renal transplant recipients, the safety and efficacy of 5% imiquimod in skin dysplasia was examined after a 16-week application, three times weekly of either imiqimod 5% cream or matching placebo cream 250 mg (l sachet) (46) . Of the 14 patients using the active cream, 7 (50%) demonstrated a reduction in skin atypia and viral warts in the treatment area compared with I (17%) of the 6 patients who received placebo. However, only 5 (36%) of 14 patients rreated with imiquimod demonstrated a reduction in the number ofAK at the end of treatment, in contrast to the 84% of patients who experienced total clearance of all AK in a double-blind, placebo-controlled study conducted in immunocompetent individuals by Stockfleth and colleagues (49) . The difference in the response rate could be explained by several hypothesis. First of all, one could argue that there was a failure to recruit effector cells because systemic immunosupression reduces T-cell function, dendritic cell trafficking and macrophage activation, therefore an increased dose of imiquimod would be required to elicit an adequate effective response. Also, there could be a site-related difference in inflammation between dorsal hand skin, which was the area tested in this study, and forehead skin and this assumption is supported by anecdotal observations in immunocompetent patients. Additionally, the important degree of hyperkeratinisation of lesions on dorsal hand skin in OTR might have required pre-treatment with keratolytic agents. Indeed, in genital warts, superior efficacy of imiquimod in females compared with males is attributed tokeratinisation of penile compared to vulvar skin. The lower degree of keratinisation and semiocclusive effects of foreskin in uncircumcised males may also account for higher clearance rates in this group compared with uncircumcised subjects. Lastly, the 3-times-weekly regimen used in this trial has been documented to be sufficient in immunocompetent individuals but might have been insufficient in treating immunosupressed patients.
Another randomized, placebo-controlled safety and efficacy study of imiquimod 5% cream applied three times weekly on Actinic Keratoses in Kidney-, Heart-, and Liver Transplant Patients (47) but using increased doses of imiquimod (500 mg versus 250 mg used in the previously mentioned trial) and treating larger surface areas (100 cm-) demonstrated more beneficial clearance rates: among patients randomized to imiquimod, the complete clearance rate was 62.1% (18/29); while for vehicle patients, the complete clearance rate was 0% (0/14). The histological assessment of a post-treatment biopsy showed in all cases that clinical clearance corresponded with the histological evaluation. With respect to the high rate ofAK progression to invasive squamous cell carcinoma and subsequent metastasis in graft recipients, this finding is relevant from a safety perspective because it confirms an actual cure of lesions also in deeper parts of the epidermis.
In a retrospective study conducted in France (52) on six patients with AK treated 3 times weekly for 16 weeks, there was one complete response (16%), three partial responses (50%) and of three patients with Bowenoid papulosis treated for 8 weeks, two showed a complete response (66%) and one a partial response(33%).
Squamous cell carcinoma and Bowen sdisease (See in situ)
Five renal transplant patients with histologicallyproven Bowen's disease treated with 5% imiquimod cream three times weekly in combination with 5% 5-fluorouracil cream applied four times weekly for 7-9 weeks had clinical clearance of their lesions with no recurrences over 3-15 months of follow-up (53) . Another study reported two renal transplant recipients and two cardiac transplant recipients also with histologically-proven Bowen's disease with 5% imiquimod cream three times weekly (54) . Three of four lesions had complete clinical clearance after an average of 6 weeks, although one lesion recurred after 10 months. Lastly, there is a solitary case of histologically-confirmed clearance of invasive SCC in an OTR treated with imiquimod applied three times weekly for 12 months (30), but this patient had however been receiving hemodialysis for the previous 5 years because of failure of his renal graft.
Warts
Imiquimod has also been used successfully to treat cutaneous and genital warts in OTR (55) . There are some published reports suggesting that imiquimod is capable of stimulating an immune response sufficient to clear HPV-induced warts without a rapid recurrence following discontinuation of treatment. Multiple palmoplantar warts in a 17year-old cardiac transplant recipient and another patient receiving immunosuppressive therapy for autoimmune hepatitis were successfully treated with a combination of C02 laser vaporization .followed by topical 5% imiquimod cream under occlusion, with no recurrences at 9-12 months (55). Application of imiquimod three times weekly for 16 weeks to perianal warts in a renal transplant recipient induced clinical clearance without recurrence over 11 months (48) . Complete resolution of recalcitrant warts on the lips of a lung transplant patient was also reported after treatment with 10 weeks ofthree times weekly topical imiquimod (15) . In an open-label, non-randomized, prospective, right/left comparison study (45) , the safety and therapeutic efficacy ofselfadministered 5% imiquimod cream was assessed for recalcitrant cutaneous warts in immunosuppressed individuals. Benefit was seen in five patients [36% in the intent-to-treat analysis (14 patients)], including more than 30% clearance of warts in three patients and reduction in overall size of warts in two further cases. This descriptive study provides preliminary evidence that topical 5% imiquimod may benefit immunosuppressed individuals with persistent cutaneous warts. Although clearance rates were relatively low, this was a group of patients with particularly recalcitrant warts. In addition to the study entry criteria of failure to respond to salicylic acid and cryotherapy, 10 had received at least one additional therapeutic modality (mean number of modalities 3.1, range 1-7). In a retrospective French study (52) , of two patients with genital warts treated 3 times weekly for a median period of 8 weeks, one showed a partial response (50%), and among 12 cutaneous wart patients treatment with the same schedule for a median period of 10 weeks, one showed complete response (8.3%) and five showed partial clearance (41.6%).
Kaposi ssarcoma
The application of imiquimod for the treatment of KS represents a completely new therapeutic approach. There is only I case report on a successful therapy of KS in a human immunodeficiency virus positive patient published recently (56) . There is a recent report (57) on a case ofKS in a renal transplant patient treated with imiquimod for 3 months with resolution of the lesions. Imiquimod treatment may therefore be used to augment the immune recognition of KS cells, and potentially reverse the effect of the immunosuppression on local immunity.
Molluscum Contagiosum
In immunocompromised patients, molluscum contagiosum lesions are often numerous, symptomatic, larger or refractory to treatment (58) . Although imiquimod is not licensed for molluscum contagiosum, its efficacy has been reported in immunocompetent and human immunodeficiency virus-positive patients (58) (59) . There has been a report (60) on the successful use of imiquimod 5% cream applied overnight three times weekly on multiple molluscum contagiosum in a renal transplant recipient. After 6 weeks of treatment there was a 50% improvement in clinical appearance, and following 6 months of continued treatment, the original lesions had largely resolved with minimal scarring. New lesions continued to appear but were easily controlled with imiquimod as required.
CONCLUSIONS
Although several mechanical and topical methods can be used to treat viral warts, precancerous and malignant lesions in OTR patients, these often require multiple visits, and can cause scarring, postinflammatory changes and pain, and may not be practical for extensive skin involvement. From the data available, it appears that the cutaneous immune system in OTR, when stimulated, retains its ability to mount an attack against viral and tumor antigens, as evidenced by the effects of imiquimod treatment in various skin diseases. At the same time, imiquimod appears as a safe option for graft viability since there was no graft rejection associated with its use in more than 100 OTR patients treated with this agent for various skin diseases. However, in large scale studies and clinical practice, a small number of patients might experience a "cytokine release" type systemic reaction, sometimes with marked symptoms. It is unknown whether this type of reaction might affect graft function/survival. Until there is more proof of the safety of imiquimod on graft viability one must always keep this scenario in mind when prescribing imiquimod to a patient with an organ graft, although the risk is small and theoretical.
On the other hand, an added advantage of imiquimod for this group of patients is the ability to treat a "field" of precancerous and verrucous lesions that could lead to an earlier identification of malignancies, which are often difficult to distinguish clinically against a background of numerous keratotic and dysplastic lesions.
It remains to be seen whether imiquimod will be the treatment used to arrest the ever-increasing burden of cutaneous neoplastic and infectious diseases that arise in OTR patients as a consequence of long-term immunosuppression. For the moment, the results are encouraging regarding the use of this promising new drug but further research and clinical trials are needed to establish the use of imiquimod as a standard treatment option available for OTR patients. 
